KalVista Pharmaceuticals (FRA:4XC1) Enterprise Value : €377.89 Mil (As of May. 27, 2024)

KalVista Pharmaceuticals Enterprise Value Chart

KalVista Pharmaceuticals Annual Data
	Trend	Dec14	Apr15	Apr16	Apr17	Apr18	Apr19	Apr20	Apr21	Apr22	Apr23
Enterprise Value		Get a 7-Day Free Trial					262.57	130.16	304.82	147.31	132.69

KalVista Pharmaceuticals Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Enterprise Value	Get a 7-Day Free Trial															98.56	132.69	195.63	166.02	404.49

Competitive Comparison of KalVista Pharmaceuticals's Enterprise Value

For the Biotechnology subindustry, KalVista Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

KalVista Pharmaceuticals's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, KalVista Pharmaceuticals's Enterprise Value distribution charts can be found below:

* The bar in red indicates where KalVista Pharmaceuticals's Enterprise Value falls into.

KalVista Pharmaceuticals Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

KalVista Pharmaceuticals's Enterprise Value for the fiscal year that ended in Apr. 2023 is calculated as

KalVista Pharmaceuticals's Enterprise Value for the quarter that ended in Jan. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

KalVista Pharmaceuticals  (FRA:4XC1) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

KalVista Pharmaceuticals's EV-to-EBIT for today is

KalVista Pharmaceuticals's current Enterprise Value is €377.89 Mil.
KalVista Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-113.84 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

KalVista Pharmaceuticals's EV-to-EBITDA for today is:

KalVista Pharmaceuticals's current Enterprise Value is €377.89 Mil.
KalVista Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-113.12 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

KalVista Pharmaceuticals's EV-to-Revenue for today is:

KalVista Pharmaceuticals's current Enterprise Value is €377.89 Mil.
KalVista Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

KalVista Pharmaceuticals Enterprise Value Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.

KalVista Pharmaceuticals (FRA:4XC1) Business Description